Table Graph
   

antiviral and associated therapy - versus lopinavir/ritonavir - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.13 [0.63, 2.05]< 10%3 studies (3/-)33.7 %some concernnot evaluable moderatecrucial-
clinical improvement 2.22 [0.80, 6.20]> 173%2 studies (2/-)93.6 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.37 [0.73, 2.56]> 10%1 study (1/-)83.8 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.80 [0.45, 7.27]> 190%2 studies (2/-)79.6 %some concernnot evaluable moderateimportant-
hospital discharge 2.00 [1.15, 3.47]> 10%1 study (1/-)99.3 %NAnot evaluable important-
mechanical ventilation 1.62 [0.85, 3.08]< 10%1 study (1/-)7.2 %NAnot evaluable important-
radiologic improvement (14-day) 1.33 [0.94, 1.88]> 10%1 study (1/-)94.7 %NAnot evaluable important-
radiologic improvement (7-day) 2.40 [0.26, 22.51]> 10%1 study (1/-)77.7 %NAnot evaluable important-
viral clearance 2.17 [0.61, 7.66]> 186%2 studies (2/-)88.5 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 4.37 [1.86, 10.25]> 10%1 study (1/-)100.0 %NAnot evaluable important-
viral clearance by day 14 1.10 [0.95, 1.26]> 10%2 studies (2/-)89.5 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.16 [0.66, 2.04]> 10%2 studies (2/-)69.6 %some concernnot evaluable moderateimportant-
ICU admission 1.23 [0.70, 2.18]< 10%1 study (1/-)23.7 %NAnot evaluable non important-
severe COVID-19 occurrence 0.30 [0.07, 1.27]< 10%1 study (1/-)94.9 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.23 [0.01, 7.12]< 10%1 study (1/-)79.4 %NAnot evaluable important-
adverse events 1.80 [0.14, 23.37]< 10%1 study (1/-)32.8 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons